On April 26, 2022 KYORIN Holdings, Inc., reported that, the Company made the following revisions to the consolidated earnings forecasts for the fiscal year ended March 31, 2022 disclosed on May 11, 2021 (at the time of the financial results announcement) based on the current business performance (Press release, Kyorin, APR 26, 2022, View Source [SID1234612945]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Revision of consolidated financial forecasts for fiscal year ended March 31, 2022
2. Reason for revision of consolidated financial forecast Forecast of consolidated net sales have been revised upward, as sales of long-listing products and generic drugs has exceeded our forecast due to effect by supply shortage triggered by quality violation stemming from several generic companies.

In terms of profits, gross profit increased owing to better than expected sales and SG&A expenses (including R & D expenses) are expected to be in line with forecast, so we have revised operating income, ordinary income and profit attributable to owners of parent upward.

There is no change to the dividend forecast announced on May 11, 2021 (annual dividend of 52 yen per share).Supplementary material

1. About Consolidated Net Sales
2. About Main Product Sales